Eversept Partners LP Raises Holdings in United Therapeutics Corporation $UTHR

Eversept Partners LP boosted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 6.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 252,592 shares of the biotechnology company’s stock after purchasing an additional 15,572 shares during the quarter. United Therapeutics comprises 6.2% of Eversept Partners LP’s holdings, making the stock its 3rd largest holding. Eversept Partners LP’s holdings in United Therapeutics were worth $123,075,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Clearstead Advisors LLC boosted its holdings in United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 23 shares in the last quarter. Independent Advisor Alliance boosted its holdings in United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 27 shares in the last quarter. Florida Financial Advisors LLC boosted its holdings in United Therapeutics by 5.4% in the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after acquiring an additional 28 shares in the last quarter. NDVR Inc. boosted its holdings in United Therapeutics by 5.1% in the fourth quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after acquiring an additional 30 shares in the last quarter. Finally, Principal Securities Inc. boosted its holdings in United Therapeutics by 4.7% in the fourth quarter. Principal Securities Inc. now owns 686 shares of the biotechnology company’s stock worth $334,000 after acquiring an additional 31 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Activity

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,540,358.40. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 636,168 shares of company stock valued at $359,249,237 in the last three months. Company insiders own 8.60% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Cantor Fitzgerald raised their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. UBS Group raised their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Stock Up 0.6%

Shares of NASDAQ:UTHR opened at $551.47 on Thursday. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The stock has a market cap of $23.41 billion, a price-to-earnings ratio of 20.36, a PEG ratio of 1.79 and a beta of 0.57. The business has a 50-day moving average price of $565.95 and a 200-day moving average price of $522.96.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the previous year, the business earned $6.63 earnings per share. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, equities analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.